Regulatory Insight: Pharma sector – long a target for antitrust enforcers
Many features of the pharmaceutical sector make it prone to…
Many features of the pharmaceutical sector make it prone to antitrust scrutiny. Intellectual property rights, in particular patents, and the promise of monopoly rents while patents remain valid, play a crucial role in incentivising new product research and development. On the other hand, the European Commission and the various national…